Pfizer Bets Big To Secure Obesity Market Place

Pfizer $4.9 billion cash acquisition of Metsera, a clinical-stage biotech focused on next-generation obesity drugs, is more than another high-profile deal in pharma’s dealmaking spree. It signals a strategic pivot: Pfizer intends to plant its flag firmly in the obesity market, one of the largest growth opportunities in the history of biopharma.

“Obesity is a large and growing space with over 200 health conditions associated with it,” Pfizer CEO Albert…